The efficacy of dextroamphetamine transdermal patch

Dextroamphetamine transdermal patch is an effective way to treat attention deficit hyperactivity disorder (ADHD) by increasing the concentration of dopamine and norepinephrine in the brain, improving the patient's cognitive function, concentration and impulse control. Compared with oral drugs, the drug release method of transdermal patches makes the blood concentration of the drug more stable, reducing fluctuations in blood drug peaks that are too high or too low, thereby effectively reducing the incidence of side effects, especially gastrointestinal discomfort.

Research shows that dextroamphetamine transdermal patches can effectively reduce ADHD symptoms in people with ADHD, including inattention, hyperactivity and impulsive behavior. Compared with traditional oral drugs, transdermal patches release drugs more uniformly and can maintain efficacy for 24 hours, helping patients maintain better concentration and self-control in daily activities. Especially for some patients who cannot tolerate the side effects of oral medications, transdermal patches provide a more ideal treatment method.

For patients with narcolepsy, dextroamphetamine transdermal patches can also effectively help improve symptoms of excessive daytime sleepiness. By increasing the brain's alertness and excitability, medications can help patients stay awake in daily life and improve concentration and alertness, especially in work or study environments that require sustained concentration for long periods of time. This can significantly improve the quality of life of narcolepsy patients.

Although the efficacy is significant, each patient's response is different, and some patients may develop drug resistance or side effects during use. Therefore, patients who use it for a long time need to communicate with their doctors regularly to evaluate the effect of the drug and adjust the dosage or treatment plan according to the actual situation. Overall, the dextroamphetamine transdermal patch is an effective and convenient treatment tool that can help patients maintain symptom relief over a longer period of time.

References: https://www.accessdata.fda.gov/drugsatfda_docs/label/2022/215401s000lbl.pdf